Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Ambrx Biopharma Inc.

    NYSE: AMAM · Real-Time Price · USD
    28.00
    0.02 (0.07%)
    At close: Mar 06, 2024, 10:00 PM

    Ambrx Biopharma Statistics

    Share Statistics

    Ambrx Biopharma has 63.29M shares outstanding. The number of shares has increased by 0% in one year.

    Shares Outstanding

    n/a
    		 63.29M

    Shares Change (YoY)

    n/a
    		 0%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 21.92M

    Failed to Deliver (FTD) Shares

    n/a
    		 848

    FTD / Avg. Volume

    n/a
    		 0.04%

    Short Selling Information

    Short Interest

    n/a
    		 n/a

    Short % of Shares Out

    n/a
    		 n/a

    Short % of Float

    n/a
    		 n/a

    Short Ratio (days to cover)

    n/a
    		 n/a

    Valuation Ratios

    The PE ratio is -1.12 and the forward PE ratio is null. Ambrx Biopharma's PEG ratio is 0.03.

    PE Ratio

    n/a
    		 -1.12

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 11.84

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 0.74

    P/FCF Ratio

    n/a
    		 -1.26

    PEG Ratio

    n/a
    		 0.03
    Financial Ratio History

    Enterprise Valuation

    Ambrx Biopharma has an Enterprise Value (EV) of 44M.

    EV / Sales

    n/a
    		 5.94

    EV / EBITDA

    n/a
    		 -0.79

    EV / EBIT

    n/a
    		 -0.64

    EV / FCF

    n/a
    		 -0.63

    Financial Position

    The company has a current ratio of 5.44, with a Debt / Equity ratio of 0.1.

    Current Ratio

    n/a
    		 5.44

    Quick Ratio

    n/a
    		 5.21

    Debt / Equity

    n/a
    		 0.1

    Debt / EBITDA

    n/a
    		 -0.21

    Debt / FCF

    n/a
    		 -0.17

    Interest Coverage

    n/a
    		 -58.97

    Financial Efficiency

    Return on Equity is -66.18% and Return on Invested Capital is -45.09%.

    Return on Equity

    n/a
    		 -66.18%

    Return on Assets

    n/a
    		 -53.07%

    Return on Invested Capital

    n/a
    		 -45.09%

    Revenue Per Employee

    n/a
    		 $85,080.46

    Profits Per Employee

    n/a
    		 $-896,505.75

    Employee Count

    n/a
    		 87

    Asset Turnover

    n/a
    		 0.05

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 1.94M

    Effective Tax Rate

    n/a
    		 -2.55%

    Stock Price Statistics

    The stock price has increased by 0% in the last 52 weeks. The beta is -2.36, so Ambrx Biopharma's price volatility has been lower than the market average.

    Beta

    n/a
    		 -2.36

    52-Week Price Change

    n/a
    		 n/a

    50-Day Moving Average

    n/a
    		 25.33

    200-Day Moving Average

    n/a
    		 15.99

    Relative Strength Index (RSI)

    n/a
    		 82.2

    Average Volume (20 Days)

    n/a
    		 1,943,941

    Income Statement

    In the last 12 months, Ambrx Biopharma had revenue of 7.4M and earned -78M in profits. Earnings per share was -2.02.

    Revenue

    n/a
    		 7.4M

    Gross Profit

    n/a
    		 7.4M

    Operating Income

    n/a
    		 -57.08M

    Net Income

    n/a
    		 -78M

    EBITDA

    n/a
    		 -55.79M

    EBIT

    n/a
    		 -64.46M

    Earnings Per Share (EPS)

    n/a
    		 -2.02
    Full Income Statement

    Balance Sheet

    The company has 55.61M in cash and 11.98M in debt, giving a net cash position of 43.63M.

    Cash & Cash Equivalents

    n/a
    		 55.61M

    Total Debt

    n/a
    		 11.98M

    Net Cash

    n/a
    		 43.63M

    Retained Earnings

    n/a
    		 -291.63M

    Total Assets

    n/a
    		 271.5M

    Working Capital

    n/a
    		 215.55M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -68.67M and capital expenditures -1.05M, giving a free cash flow of -69.73M.

    Operating Cash Flow

    n/a
    		 -68.67M

    Capital Expenditures

    n/a
    		 -1.05M

    Free Cash Flow

    n/a
    		 -69.73M

    FCF Per Share

    n/a
    		 -1.81
    Full Cash Flow Statement

    Margins

    Gross margin is 100%, with operating and profit margins of -771.16% and -1053.72%.

    Gross Margin

    n/a
    		 100%

    Operating Margin

    n/a
    		 -771.16%

    Pretax Margin

    n/a
    		 -1027.55%

    Profit Margin

    n/a
    		 -1053.72%

    EBITDA Margin

    n/a
    		 -753.69%

    EBIT Margin

    n/a
    		 -771.16%

    FCF Margin

    n/a
    		 -942.03%

    Dividends & Yields

    AMAM does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 -89%

    FCF Yield

    n/a
    		 -79.57%
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for AMAM.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 34.85

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist